KROMATID completed $8 million Series C Round funding
Sector:
Software
Life Science
08/20/2025
Longmont, CO USA
KROMATID
completed $8 million Series C Round funding. Investors include
BroadOak Capital Partners (lead).
"We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients."
About
KROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
